3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
11
Terminated
4
Unknown
3
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Burkitt Lymphoma
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Leukemia, Biphenotypic, Acute
2
Skin Neoplasms
1
Shwachman-Diamond Syndrome
1
Recurrence
1
Primary Immunodeficiency Diseases
1
Oropharyngeal Neoplasms
1
Neutropenia, Severe Congenital, Autosomal Recessive 3
1
Myelodysplastic Syndromes
1
Melanoma
1
Macrophage Activation Syndrome
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
Lymphohistiocytosis, Hemophagocytic
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Histiocytosis, Langerhans-Cell
1
Histiocytosis
1
Hemoglobinopathies
1
Drug-Related Side Effects and Adverse Reactions
1
Down Syndrome
1
Cranial Nerve Diseases
1
Colitis
1
Interventions
Dexamethasone
18
Cyclophosphamide
16
fludarabine
11
pomalidomide
9
pembrolizumab
9
carfilzomib
9
daratumumab
7
Rituximab
7
Lenalidomide
7
Calcium Dobesilate
7
fludarabine phosphate
6
Gemcitabine
6
Cisplatin
6
Bortezomib
6
venetoclax
5
elotuzumab
4
isatuximab
3
blinatumomab
3
Vincristine
3
Radiotherapy
3
Prednisone
3
Etoposide
3
Doxorubicin
3
Cytarabine
3
tisagenlecleucel
2
selinexor
2
ruxolitinib
2
ixazomib
2
dexamethasone 21-phosphate
2
cabazitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Recurrence
×
Methylprednisolone
×
Clear all
NCT06097364
2026-02-06
OLYMPIA-2
Regeneron Pharmaceuticals
Phase 3
Active not recruiting
733 enrolled